235 related articles for article (PubMed ID: 29091299)
21. DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity.
Xie L; Wang PX; Zhang P; Zhang XJ; Zhao GN; Wang A; Guo J; Zhu X; Zhang Q; Li H
J Hepatol; 2016 Jul; 65(1):113-124. PubMed ID: 27016281
[TBL] [Abstract][Full Text] [Related]
22. Tumor Progression Locus 2 in Hepatocytes Potentiates Both Liver and Systemic Metabolic Disorders in Mice.
Gong J; Fang C; Zhang P; Wang PX; Qiu Y; Shen LJ; Zhang L; Zhu XY; Tian S; Li F; Wang Z; Huang Z; Wang A; Zhang XD; She ZG
Hepatology; 2019 Feb; 69(2):524-544. PubMed ID: 29381809
[TBL] [Abstract][Full Text] [Related]
23. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis.
Hou J; Zhang J; Cui P; Zhou Y; Liu C; Wu X; Ji Y; Wang S; Cheng B; Ye H; Shu L; Zhang K; Wang D; Xu J; Shu Q; Colonna M; Fang X
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586673
[TBL] [Abstract][Full Text] [Related]
24. Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Metabolic Dysfunctions in Nonalcoholic Fatty Liver Disease in Mice.
Zhao Y; Wang F; Gao L; Xu L; Tong R; Lin N; Su Y; Yan Y; Gao Y; He J; Kong L; Yuan A; Zhuge Y; Pu J
Hepatology; 2018 Sep; 68(3):897-917. PubMed ID: 29573006
[TBL] [Abstract][Full Text] [Related]
25. Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease.
Stacchiotti A; Favero G; Lavazza A; Golic I; Aleksic M; Korac A; Rodella LF; Rezzani R
PLoS One; 2016; 11(1):e0148115. PubMed ID: 26824477
[TBL] [Abstract][Full Text] [Related]
26. SARM1 deletion restrains NAFLD induced by high fat diet (HFD) through reducing inflammation, oxidative stress and lipid accumulation.
Pan ZG; An XS
Biochem Biophys Res Commun; 2018 Apr; 498(3):416-423. PubMed ID: 29454967
[TBL] [Abstract][Full Text] [Related]
27. Deletion of Macrophage Mineralocorticoid Receptor Protects Hepatic Steatosis and Insulin Resistance Through ERα/HGF/Met Pathway.
Zhang YY; Li C; Yao GF; Du LJ; Liu Y; Zheng XJ; Yan S; Sun JY; Liu Y; Liu MZ; Zhang X; Wei G; Tong W; Chen X; Wu Y; Sun S; Liu S; Ding Q; Yu Y; Yin H; Duan SZ
Diabetes; 2017 Jun; 66(6):1535-1547. PubMed ID: 28325853
[TBL] [Abstract][Full Text] [Related]
28. Activation of the Hypoxia Inducible Factor 1α Subunit Pathway in Steatotic Liver Contributes to Formation of Cholesterol Gallstones.
Asai Y; Yamada T; Tsukita S; Takahashi K; Maekawa M; Honma M; Ikeda M; Murakami K; Munakata Y; Shirai Y; Kodama S; Sugisawa T; Chiba Y; Kondo Y; Kaneko K; Uno K; Sawada S; Imai J; Nakamura Y; Yamaguchi H; Tanaka K; Sasano H; Mano N; Ueno Y; Shimosegawa T; Katagiri H
Gastroenterology; 2017 May; 152(6):1521-1535.e8. PubMed ID: 28088462
[TBL] [Abstract][Full Text] [Related]
29. Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3.
Fang J; Ji YX; Zhang P; Cheng L; Chen Y; Chen J; Su Y; Cheng X; Zhang Y; Li T; Zhu X; Zhang XJ; Wei X
Hepatology; 2020 May; 71(5):1592-1608. PubMed ID: 31529495
[TBL] [Abstract][Full Text] [Related]
30. Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: potential role of PPARγ.
Xu E; Forest MP; Schwab M; Avramoglu RK; St-Amand E; Caron AZ; Bellmann K; Shum M; Voisin G; Paquet M; Montoudis A; Lévy E; Siminovitch KA; Neel BG; Beauchemin N; Marette A
Hepatology; 2014 May; 59(5):1803-15. PubMed ID: 24327268
[TBL] [Abstract][Full Text] [Related]
31. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
32. Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD.
Hu Y; He W; Huang Y; Xiang H; Guo J; Che Y; Cheng X; Hu F; Hu M; Ma T; Yu J; Tian H; Tian S; Ji YX; Zhang P; She ZG; Zhang XJ; Huang Z; Yang J; Li H
Hepatology; 2021 Nov; 74(5):2508-2525. PubMed ID: 34231239
[TBL] [Abstract][Full Text] [Related]
33. Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta-Activated Kinase 1-c-Jun-N-Terminal Kinase/p38 Signaling.
Wang J; Ma J; Nie H; Zhang XJ; Zhang P; She ZG; Li H; Ji YX; Cai J
Hepatology; 2021 Jan; 73(1):104-125. PubMed ID: 32191345
[TBL] [Abstract][Full Text] [Related]
34. Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model.
Lee S; Son B; Jeon J; Park G; Kim H; Kang H; Youn H; Jo S; Song JY; Youn B
Cell Physiol Biochem; 2018; 47(6):2233-2249. PubMed ID: 29975946
[TBL] [Abstract][Full Text] [Related]
35. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1α regulation in vitro and in vivo.
Park MJ; Kim DI; Lim SK; Choi JH; Kim JC; Yoon KC; Lee JB; Lee JH; Han HJ; Choi IP; Kim HC; Park SH
J Hepatol; 2014 Nov; 61(5):1151-7. PubMed ID: 25003952
[TBL] [Abstract][Full Text] [Related]
36. Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease.
Li S; Wang X; Zhang J; Li J; Liu X; Ma Y; Han C; Zhang L; Zheng L
Braz J Med Biol Res; 2018; 51(8):e7299. PubMed ID: 29924135
[TBL] [Abstract][Full Text] [Related]
37. iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling.
Deng X; Wang J; Jiao L; Utaipan T; Tuma-Kellner S; Schmitz G; Liebisch G; Stremmel W; Chamulitrat W
Biochim Biophys Acta; 2016 May; 1861(5):449-61. PubMed ID: 26873633
[TBL] [Abstract][Full Text] [Related]
38. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
[TBL] [Abstract][Full Text] [Related]
39. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
[TBL] [Abstract][Full Text] [Related]
40. Osteoprotegerin Promotes Liver Steatosis by Targeting the ERK-PPAR-γ-CD36 Pathway.
Zhang C; Luo X; Chen J; Zhou B; Yang M; Liu R; Liu D; Gu HF; Zhu Z; Zheng H; Li L; Yang G
Diabetes; 2019 Oct; 68(10):1902-1914. PubMed ID: 31292134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
